<DOC>
	<DOCNO>NCT00424853</DOCNO>
	<brief_summary>This multicenter , open-label , randomized phase II trial whose aim assess antitumor activity two sequential schedule docetaxel cisplatin follow gemcitabine .</brief_summary>
	<brief_title>ADVANCED Phase II Trial Weekly v 3 Weekly Docetaxel Cisplatin Followed Gemcitabine Non-small-cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis NSCLC ; Histologic subtypes may include large cell , squamous cell , adenocarcinoma generic cytological diagnosis NSCLC ; Patients must locoregionally advance unresectable non metastatic NSCLC Stage IIIB ( N3 supraclavicular T4 pleural effusion ) Stage IV accord revise International Staging System ; Patients must least one measurable lesion accord RECIST criterion . Previous radical surgery ( 30 day study entry ) allow pathologic proof progression neoplastic disease must document ; WHO Performance Status 0 1 ; Weight loss &lt; 5 % within last 3 month ; Laboratory requirement entry Blood cell count : Absolute neutrophils &gt; 2.0 . 10^9/L ; Platelets &gt; 100 . 10^9/L ; Hemoglobin &gt; 10 g/dl Renal function : Serum creatinine &lt; 1 upper normal limit ( UNL ) . In case limit value serum creatinine , creatinine clearance &gt; 60 mL/min Hepatic function : Serum bilirubin &lt; 1 x UNL ; ASAT ALAT &lt; 2.5 x UNL ; Alkaline phosphatase &lt; 5 x UNL ( unless accompany extensive bone metastasis ) Prior systemic chemotherapy immunotherapy ; prior neoadjuvant adjuvant chemotherapy allow end least 12 month enrollment ; Prior radiotherapy NSCLC measurable lesion . Prior radiotherapy ( &lt; 25 % bone marrow ) allow non target lesion . At least 4 week must elapse since completion radiotherapy patient must side effect recover . Cytohistological diagnosis small cell lung cancer , carcinoid , mixed smallcell / nonsmall cell lung cancer ; Patients evaluable , measurable disease ( non target lesion ) ; Patients symptomatic brain metastasis leptomeningeal disease ; History prior malignancy , except cure non melanoma skin cancer , curatively treat situ carcinoma cervix cancer curatively treat evidence disease least five year ; History hypersensitivity reaction polysorbate 80 ; Pregnant lactate woman ( woman childbearing potential must use adequate contraception ) ; Current peripheral neuropathy NCI grade &gt; 2 ; Significant neurological psychiatric disorder ; Participation clinical trial experimental agent within 30 day study entry ; Other serious concomitant illness medical condition : 1 . Uncontrolled cardiovascular disease ; 2 . History significant neurologic psychiatric disorder include demential seizure ; 3 . Active infection require iv antibiotic ; 4 . Active ulcer , unstable diabetes mellitus contraindication corticotherapy ; 5 . Any condition judgement investigator would place subject undue risk interfere study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>